01 / What it is
Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue and a ghrelin-receptor agonist. It is characterized in the literature as one of the most selective compounds in its class.
Research use onlySpecification publishedQualified users only
Endocrine & growth-factor research · AGX-07
Ipamorelin
The selective pentapeptide secretagogue
$60
10 mg lyophilized vial$6.00/mg · research use only
Research use only · no human or veterinary use, consumption, administration, diagnosis, treatment, prevention, cosmetic use, or food use. Sold to qualified laboratory and analytical users.
02 / Mechanism in the literature
It binds the growth-hormone secretagogue receptor (GHS-R1a) to prompt pituitary GH release. Research describes its selectivity as its defining trait: unlike earlier GHRPs, it shows minimal effect on cortisol and prolactin signaling in study models.
03 / Research context
Ipamorelin appears in endocrine and GH-axis literature, often as a selective comparator against earlier growth-hormone-releasing peptides.
Listed format10 mg lyophilized vial
SequenceAib-His-D-2-Nal-D-Phe-Lys-NH₂
Molecular formulaC38H49N9O5
Molecular weight712 g/mol
Catalogue referenceAGX-07
Listed price$60
TargetGhrelin / GHS receptor
04 / Common questions
How does it differ from tesamorelin?
They act on different receptors — tesamorelin on the GHRH receptor, ipamorelin on the ghrelin/GHS receptor — which is why the literature often studies the two pathways separately.
Why is selectivity emphasized?
Earlier growth-hormone-releasing peptides also moved cortisol and prolactin in research models; ipamorelin is characterized as largely sparing those pathways.